AR065316A1 - Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales - Google Patents

Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales

Info

Publication number
AR065316A1
AR065316A1 ARP080100602A ARP080100602A AR065316A1 AR 065316 A1 AR065316 A1 AR 065316A1 AR P080100602 A ARP080100602 A AR P080100602A AR P080100602 A ARP080100602 A AR P080100602A AR 065316 A1 AR065316 A1 AR 065316A1
Authority
AR
Argentina
Prior art keywords
chitosan
acceptable salt
chitosans
physiologically acceptable
nail
Prior art date
Application number
ARP080100602A
Other languages
English (en)
Inventor
Federico Mailland
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065316(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of AR065316A1 publication Critical patent/AR065316A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A61Q3/02—Nail coatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

Uso de quitosanos, derivados de quitosano y sales fisiologicamente aceptables de éstos para el tratamiento de enfermedades inflamatorias ungueales. La presente también se dirige al uso de quitosanos, un derivado de quitosano o una sal fisiologicamente aceptable del mismo, para acelerar el ritmo de crecimiento de la una. La presente además está dirigida al uso de quitosanos para acelerar el ritmo de crecimiento de las unas durante el tratamiento de enfermedades ungueales, distrofia ungueal u otras afecciones ungueales, para acortar de forma considerable los tratamientos específicos de dichas enfermedades ungueales, distrofia ungueal u otras afecciones ungueales. Reivindicacion 1: Quitosano, derivado de quitosano soluble en agua y/o una sal fisiologicamente aceptable de éste, caracterizado porque es usado para la aceleracion del ritmo de crecimiento de la una. Reivindicacion 8: Quitosano, derivado de quitosano soluble en agua y/o una sal fisiologicamente aceptable de éste, de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizado porque se administra en combinacion con uno o más principios activos. Reivindicacion 9: Quitosano, derivado de quitosano soluble en agua y/o una sal fisiologicamente aceptable de éste, de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizado porque dicho principio activo es para el tratamiento de una enfermedad de la una. Reivindicacion 11: Quitosano, derivado de quitosano soluble en agua y/o una sal fisiologicamente aceptable de éste, de acuerdo con la reivindicacion 9, caracterizado porque dicho principio activo se selecciona de corticosteroides, agentes antipsoriásicos, agentes inmunosupresores, agentes antimicoticos, agentes antisépticos, humectantes, y/o agentes fortalecedores de unas. Reivindicacion 12: Quitosano, derivado de quitosano soluble en agua y/o una sal fisiologicamente aceptable de éste, de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizado porque se administra en forma topica.
ARP080100602A 2007-02-14 2008-02-12 Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales AR065316A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07102335A EP1958638A1 (en) 2007-02-14 2007-02-14 Use of chitosans to increase nail growth rate

Publications (1)

Publication Number Publication Date
AR065316A1 true AR065316A1 (es) 2009-05-27

Family

ID=38345983

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100602A AR065316A1 (es) 2007-02-14 2008-02-12 Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales

Country Status (32)

Country Link
US (3) US8680074B2 (es)
EP (3) EP1958638A1 (es)
JP (3) JP5426401B2 (es)
KR (2) KR101131015B1 (es)
CN (2) CN102988405A (es)
AR (1) AR065316A1 (es)
AT (1) ATE522221T1 (es)
AU (1) AU2008214693B2 (es)
BR (1) BRPI0807595A2 (es)
CA (1) CA2677715C (es)
CL (2) CL2008000444A1 (es)
CO (1) CO6230979A2 (es)
CY (2) CY1112058T1 (es)
DK (2) DK2377541T3 (es)
EA (2) EA201270116A1 (es)
ES (2) ES2436647T3 (es)
HK (1) HK1133189A1 (es)
HR (2) HRP20110667T1 (es)
IL (1) IL200269A (es)
MA (1) MA31236B1 (es)
ME (1) ME00830B (es)
MX (1) MX2009008686A (es)
MY (2) MY163297A (es)
NZ (1) NZ578896A (es)
PH (1) PH12014500274A1 (es)
PL (2) PL2377541T3 (es)
PT (2) PT2377541E (es)
RS (2) RS53143B (es)
SI (2) SI2377541T1 (es)
UA (1) UA100011C2 (es)
WO (1) WO2008098869A2 (es)
ZA (1) ZA200905443B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201490B2 (en) 2007-02-14 2019-02-12 Polichem Sa Use of chitosans for the treatment of nail inflammatory diseases
WO2010109423A1 (en) * 2009-03-25 2010-09-30 Sulur Subramaniam Vanangamudi A medicinal antifungal and steroids cream comprising chitosan and a process to make it
EP2763649A2 (en) * 2011-10-05 2014-08-13 Allergan, Inc. Compositions for enhancing nail health
PT2793946T (pt) * 2011-12-20 2019-05-08 Urgo Rech Innovation Et Developpement Composição tópica filmogénica e uso da mesma para tratar ou prevenir a onicofagia
US8697753B1 (en) 2013-02-07 2014-04-15 Polichem Sa Method of treating onychomycosis
EP2845597A1 (en) * 2013-09-10 2015-03-11 Polichem S.A. Hydroxypropyl chitosan for the treatment of onychomycosis
EP2910245A1 (en) * 2014-02-21 2015-08-26 Polichem SA Topical antifungal composition for treating onychomycosis
CN109893472A (zh) * 2019-04-09 2019-06-18 涿州皓原箔业有限公司 一种环保无毒水性卸甲液及其制备方法
ES2834732B2 (es) * 2019-12-17 2022-03-24 Univ Valladolid Solucion acuosa que comprende un complejo de inclusion, metodo de obtencion y su uso para aplicacion en cultivos y la mejora de su rendimiento
CN111388416B (zh) * 2020-02-26 2022-03-08 浙江康德药业集团股份有限公司 一种盐酸利多卡因胶浆剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3541305A1 (de) * 1985-11-22 1987-05-27 Wella Ag Kosmetische mittel auf der basis von n-hydroxypropylchitosanen, neue n-hydroxypropyl-chitosane sowie verfahren zu ihrer herstellung
DE3723811A1 (de) * 1987-07-18 1989-01-26 Wella Ag Nagellack auf der basis von o-benzyl-n-hydroxyalkylchitosanen sowie neue o-benzyl-n-hydroxyalkylderivate des chitosans
CA2008775C (en) * 1989-02-24 1998-12-22 Alberto Ferro Nail lacquer
EP0615745B1 (en) 1993-02-19 1997-05-02 Howard Green Compositions containing corneocyte proteins
FR2718637A1 (fr) * 1994-04-15 1995-10-20 Oreal Composition cosmétique à appliquer sur l'ongle.
RU2108114C1 (ru) * 1996-12-27 1998-04-10 Товарищество с ограниченной ответственностью Научно-производственное предприятие "Эрлон", Лтд. Биологическая композиция для лечения ран "коллахит"
ITTO980264A1 (it) 1998-03-26 1999-09-26 Silvio Rossi Applicazione di un estratto basico non quaternario della peschiera fuchsiaefolia ad attivita' antimalarica
US6391334B1 (en) * 1999-10-25 2002-05-21 Amway Corporation Barrier-forming composition
DE10035991A1 (de) 2000-07-24 2002-02-14 Polichem Sa Nagellackzusammensetzung
ATE411032T1 (de) * 2001-12-14 2008-10-15 Dnp Canada Inc Verwendungen von chitosanoligosacchariden
EP1440683A1 (de) * 2003-01-23 2004-07-28 Cognis France S.A. Verwendung von Oligoglucosaminen in kosmetischen oder dermatologischen Zubereitungen
EP1491202A1 (en) * 2003-06-23 2004-12-29 Polichem S.A. Nail restructuring compositions for topical application
JP3881992B2 (ja) 2004-07-30 2007-02-14 シャープ株式会社 受信装置、受信プログラム、および受信プログラムを記録した記録媒体
WO2006111426A1 (en) * 2005-04-19 2006-10-26 Galderma S.A. Composition of film-forming solution type, comprising vitamin d or a derivative thereof and a corticosteroid, and use thereof in dermatology
FR2892023B1 (fr) * 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102006049585A1 (de) * 2006-10-22 2008-04-24 Susilo, Rudy, Dr. Nagellack für kosmetische und medizinische Anwendungen

Also Published As

Publication number Publication date
HRP20131175T1 (hr) 2014-01-17
SI2117564T1 (sl) 2011-12-30
EA018390B1 (ru) 2013-07-30
AU2008214693A2 (en) 2009-09-10
KR101131015B1 (ko) 2012-03-29
PL2117564T3 (pl) 2012-03-30
CN102988405A (zh) 2013-03-27
ES2369116T3 (es) 2011-11-25
UA100011C2 (ru) 2012-11-12
US8680074B2 (en) 2014-03-25
ZA200905443B (en) 2010-10-27
JP2013213048A (ja) 2013-10-17
EA201270116A1 (ru) 2012-06-29
SI2377541T1 (sl) 2014-01-31
RS53143B (en) 2014-06-30
JP6045663B2 (ja) 2016-12-14
PH12014500274A1 (en) 2016-06-06
CL2013002052A1 (es) 2014-02-21
CA2677715A1 (en) 2008-08-21
HRP20110667T1 (hr) 2011-10-31
BRPI0807595A2 (pt) 2014-07-22
RS52031B (en) 2012-04-30
US20160015620A1 (en) 2016-01-21
KR101323762B1 (ko) 2013-11-01
ME00830B (me) 2012-03-20
EP2117564B1 (en) 2011-08-31
EP2117564A2 (en) 2009-11-18
MA31236B1 (fr) 2010-03-01
MX2009008686A (es) 2009-08-21
CO6230979A2 (es) 2010-12-20
EP2377541A1 (en) 2011-10-19
JP2015221823A (ja) 2015-12-10
JP2010518138A (ja) 2010-05-27
CN101663039B (zh) 2013-08-07
PT2117564E (pt) 2011-10-17
EP1958638A1 (en) 2008-08-20
CL2008000444A1 (es) 2008-08-22
MY154499A (en) 2015-06-30
CA2677715C (en) 2014-10-14
KR20090121312A (ko) 2009-11-25
JP5426401B2 (ja) 2014-02-26
WO2008098869A3 (en) 2008-10-09
KR20110075043A (ko) 2011-07-05
NZ578896A (en) 2012-02-24
DK2377541T3 (da) 2013-11-11
US20140147401A1 (en) 2014-05-29
MY163297A (en) 2017-09-15
IL200269A0 (en) 2010-04-29
CY1115136T1 (el) 2016-12-14
ATE522221T1 (de) 2011-09-15
US20100152133A1 (en) 2010-06-17
IL200269A (en) 2015-10-29
EA200901093A1 (ru) 2010-02-26
AU2008214693A1 (en) 2008-08-21
US9173827B2 (en) 2015-11-03
DK2117564T3 (da) 2011-10-17
PL2377541T3 (pl) 2014-04-30
HK1133189A1 (en) 2010-03-19
CY1112058T1 (el) 2015-11-04
ES2436647T3 (es) 2014-01-03
CN101663039A (zh) 2010-03-03
WO2008098869A2 (en) 2008-08-21
AU2008214693B2 (en) 2013-05-02
EP2377541B1 (en) 2013-10-23
PT2377541E (pt) 2013-11-21

Similar Documents

Publication Publication Date Title
AR065316A1 (es) Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
JP2014505733A5 (es)
CO6150136A2 (es) Combinacion de adapaleno y peroxido de benzoilo para tratar lesiones de acne
RU2013121788A (ru) Ингибиторы репликации вич
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
ES2721898T3 (es) Formulaciones estables para liofilizar partículas terapéuticas
WO2009043437A3 (en) Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections
JP2010222367A5 (es)
WO2009046859A3 (en) Use of af12198 and dago as therapeutic agents
CL2012000446A1 (es) Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios.
WO2009039982A3 (en) Use of gip alone or in combination with dynorphin b as a therapeutic agent
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
BR112012021638A2 (pt) composição livre de conservantes estéril ótica farmacêutica na forma de uma solução aquosa clara.
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
AR065317A1 (es) Uso de quitosanos, derivados de quitosanos y una sal fisiologicamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
WO2010009369A3 (en) Methods and materials for the treatment of acne
WO2009102808A3 (en) Doxorubicin adjuvants to reduce toxicity and methods for using the same
UY29989A1 (es) Composiciones farmacéuticas de agentes hipnoticos de accion corta en forma de liberación modificada y los procedimientos para preparar dichas formulaciones
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes

Legal Events

Date Code Title Description
FB Suspension of granting procedure